Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wuxi Biologics Cayman Inc ADR (OP: WXXWY )

2.690 -0.010 (-0.37%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 45,577
Open 2.700
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 2.700
Today's Range 2.640 - 2.700
52wk Range 2.640 - 13.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target... 
Via Benzinga

Performance

YTD
-63.00%
-63.00%
1 Month
-12.09%
-12.09%
3 Month
-19.94%
-19.94%
6 Month
-58.74%
-58.74%
1 Year
-74.77%
-74.77%

More News

Read More
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Via Talk Markets
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Via Talk Markets
Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement
Via Talk Markets
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Via Talk Markets
Strong Consumer Turnout Drives Hong Kong Stocks Higher Friday As China's Former Premier Li Keqiang Dies At 68
Via Benzinga
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
Via Talk Markets
Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact
Via Talk Markets
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion
Via Talk Markets
Wuxi Biologics Will Be Removed From U.S. Commerce Department's ‘Unverified List’
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.